Dexcom Inc DXCM:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 6:27 PM EDT73.34
+0.57 (+0.78%)
+0.57 (+0.78%)Volume
341,292
Close
72.77
-0.68 (-0.93%)
-0.68 (-0.93%)Volume
3,706,148
52 week range
54.11 - 89.98
- Open73.00
- Day High73.25
- Day Low71.95
- Prev Close73.45
- 52 Week High89.98
- 52 Week High Date07/30/25
- 52 Week Low54.11
- 52 Week Low Date11/07/25
Latest On Dexcom Inc
Key Stats
- Market Cap28.08B
- Shares Out385.87M
- 10 Day Average Volume7.43M
- Dividend-
- Dividend Yield-
- Beta1.44
Latest On Dexcom Inc
KEY STATS
- Open73.00
- Day High73.25
- Day Low71.95
- Prev Close73.45
- 52 Week High89.98
- 52 Week High Date07/30/25
- 52 Week Low54.11
- 52 Week Low Date11/07/25
- Market Cap28.08B
- Shares Out385.87M
- 10 Day Average Volume7.43M
- Dividend-
- Dividend Yield-
- Beta1.44
RATIOS/PROFITABILITY
- EPS (TTM)2.32
- P/E (TTM)31.39
- Fwd P/E (NTM)27.30
- EBITDA (TTM)1.385B
- ROE (TTM)35.62%
- Revenue (TTM)4.818B
- Gross Margin (TTM)63.43%
- Net Margin (TTM)19.31%
- Debt To Equity (MRQ)43.81%
EVENTS
- Earnings Date07/28/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREDexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes...
Kevin Sayer
Executive Chairman of the Board
Jacob Leach
President, Chief Executive Officer, Director
Jereme Sylvain
Chief Financial Officer, Executive Vice President
Michael Brown
Executive Vice President, Chief Legal Officer
Jon Coleman
Executive Vice President, Chief Commercial Officer
Address
6340 Sequence Drive
San Diego, CA
92121
United States